Alzheimer’sdisease (AD) is a progressive neurodegenerative disorder, characterized by senile plaques constituting extracellular deposits of β-amyloid (Aβ) fibrils. Since Aβ accumulation in the brain is considered an early event preceding, by decades, cognitive dysfunction, disease-modifying treatments are aimed at facilitating clearance of this protein from the brain or ameliorating its toxic effects. Recent studies have identified the amylin receptor as a capable mediator of the deleterious actions of Aβ and furthermore, administration of amylin receptor-based peptides has been shown to improve spatial memory and learning in transgenic mouse models of AD. Here, by discussing available evidence, we posit that the amylin receptor could be considered a potential therapeutic target for AD, and present the rationale for using amylin receptor antagonists to treat this debilitating condition.

阿尔茨海默氏病（AD）是一种进行性神经退行性疾病，其特征在于老年斑构成β-淀粉样蛋白（Aβ）原纤维的细胞外沉积物。由于Aβ在大脑中的积聚被认为是认知功能障碍的几十年前的早期事件，因此，疾病缓解疗法旨在促进该蛋白从大脑中清除或减轻其毒性作用。最近的研究已经确定了胰岛淀粉样多肽受体是Aβ有害作用的有效介体，此外，基于胰岛淀粉样多肽受体的肽的给药已显示可改善AD的转基因小鼠模型中的空间记忆和学习能力。在这里，通过讨论现有证据，我们认为胰岛淀粉样多肽受体可以被认为是AD的潜在治疗靶点，